With a rich 300 million market cap to drag it down, this company...

With a rich 300 million market cap to drag it down, this company is going nowhere until it has millions in drug sales. And, as of right now, Ropren isn't even in Phase III trials.

I watch with interest to see what the capital raising price will be. They will have to raise quite a bit to fund the expensive clinical trials, or take on a partner and dilute the company.

The share price has gone up too fast, too soon. Many people are sitting on huge profits, and will take them at the first sniff of trouble. Don't be the last one to turn out the lights.